• Navigating EMA Requirements with Precision siRNA Biodistribution Data.*

What are the EMA’s primary expectations for siRNA biodistribution data in a nonclinical package?

A: The EMA expects a comprehensive characterization of the absorption, distribution, metabolism, and excretion (ADME) profile for both the siRNA active substance and its delivery vehicle, typically a lipid nanoparticle (LNP). Data must demonstrate tissue accumulation, clearance rates, and potential for non-target exposure using validated, sensitive quantitative assays.

How does the choice of lipid nanoparticle (LNP) formulation impact the design of a biodistribution study?

A: The LNP’s composition dictates the pharmacokinetic profile and tissue tropism of the siRNA payload. The study design must account for the LNP’s stability, clearance mechanism, and potential for lipid accumulation. Bioanalytical strategies must be capable of independently quantifying both the LNP components and the siRNA to understand their relationship in vivo.

Which quantitative methods are most suitable for detecting siRNA in tissues?

A: Quantitative reverse transcription PCR (qRT-PCR) is the standard for its high sensitivity and specificity in quantifying siRNA from complex tissue matrices. Hybridization-based assays, such as branched DNA (bDNA) assays, offer an alternative with high throughput. The selection depends on the required limit of quantification (LOQ) and the specific characteristics of the siRNA sequence.

For non-target tissue biodistribution, what level of tissue sampling is considered standard for an EMA submission?

A: A comprehensive panel is required. This includes the target organ(s), major organs of potential accumulation and toxicity (liver, spleen, kidneys), organs of elimination, injection site, and circulatory components (plasma, whole blood). Additional tissues may be required based on the LNP’s properties or findings from initial studies.

Successful EMA submissions for siRNA therapeutics require a nonclinical data package that rigorously defines the asset’s pharmacokinetic (PK) and biodistribution profile. This involves quantifying both the siRNA payload and its lipid nanoparticle (LNP) delivery system across a comprehensive set of target and non-target tissues. Franklin Biolabs executes these studies within a GxP framework, leveraging highly sensitive bioanalytical assays to generate the precise data required to meet regulatory expectations and support a typical 18-24 month IND timeline.

The transient nature and targeted mechanism of siRNA require a bioanalytical approach distinct from that of other biologics. The primary objective is to build a quantitative map of where the LNP carrier and its siRNA payload travel, accumulate, and are cleared following administration.

Key study design considerations include:

• Assay Specificity: Developing assays that can distinguish the intact siRNA from its metabolites.

• Matrix Effects: Validating assay performance across diverse tissues, from blood and liver to kidney and spleen, to ensure data accuracy.

• Dynamic Range: Ensuring methods possess the sensitivity to detect low concentrations at later time points and the range to quantify high concentrations in target tissues.

We develop custom qRT-PCR and hybridization-based assays to provide a clear, quantitative picture of a therapeutic’s in vivo journey.

The consistency of the LNP delivery vehicle is a variable that must be controlled to generate reproducible preclinical data. As research from academic and industry consortia has shown, the method of LNP production directly influences the particle’s characteristics, which in turn governs in vivo delivery efficiency and potency (PMID: 34189917). For a regulatory submission, demonstrating that the LNP formulation used in pivotal nonclinical studies is representative of the clinical-grade material is a point of significant scrutiny. This requires robust characterization and a scalable manufacturing process, a capability supported by Franklin Biolabs’ strategic partners.

Our biodistribution studies are conducted in a >100,000 sq ft, GxP-compliant facility, integrating bioanalysis with our comprehensive Histology services for a complete assessment. This infrastructure supports our clients’ programs, contributing to a 100% IND success rate for all programs initiated since 2019. (The Franklin Biolabs brand was launched in 2024).

All in vivo studies are performed in full compliance with AAALAC and USDA guidelines. Our study designs incorporate the 3Rs principles (Replacement, Reduction, and Refinement) to maximize data acquisition from each animal, thereby minimizing the number of subjects required while upholding the highest ethical standards. This approach ensures the scientific integrity of the data package submitted to regulatory bodies like the EMA.